For research use only. Not for use in humans.

Odronextamab (Anti-CD20 & CD3)

Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.

Odronextamab (Anti-CD20 & CD3)

Quality Control

  • Cited in Nature Medicine for its top-tier quality
  • SDS
  • Datasheet

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 0
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Odronextamab is a fully humanized, hinge-stabilized IgG4 bispecific antibody targeting CD20 on B cells and CD3 on T cells. It engages cytotoxic T cells to eliminate malignant B cells and exhibits potent efficacy in relapsed/refractory B-cell non-Hodgkin lymphoma. M.W 145.57 kDa.

Product Details

CAS No. 1801338-64-6
Source CHO
Storage
(From the date of receipt)
-80℃(avoid freeze-thaw cycles)

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.